SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates.
Lancet
; 396(10262): 1595-1606, 2020 11 14.
Article
in English
| MEDLINE | ID: covidwho-857279
ABSTRACT
Understanding immune responses to severe acute respiratory syndrome coronavirus 2 is crucial to understanding disease pathogenesis and the usefulness of bridge therapies, such as hyperimmune globulin and convalescent human plasma, and to developing vaccines, antivirals, and monoclonal antibodies. A mere 11 months ago, the canvas we call COVID-19 was blank. Scientists around the world have worked collaboratively to fill in this blank canvas. In this Review, we discuss what is currently known about human humoral and cellular immune responses to severe acute respiratory syndrome coronavirus 2 and relate this knowledge to the COVID-19 vaccines currently in phase 3 clinical trials.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Viral Vaccines
/
Coronavirus Infections
/
Pandemics
/
Betacoronavirus
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Lancet
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS